Sari Lerner

Sari Lerner is an associate in the firm’s Life Sciences group. Sari’s practice covers all phases of the corporate life cycle, including startup and formation matters, venture financings and initial public offerings, with a focus on representing both public companies and investment banks in connection with a variety of capital markets transactions. Sari also counsels clients on ongoing securities law compliance and corporate governance matters. Sari joined Goodwin in 2023. 

Sari’s experience includes, among others, representation of:

• Underwriters in a $150 million follow-on offering of Atai Life Sciences N.V securities
• The agents in multiple “at-the-market” transaction programs, including those of Humacyte, Inc., Atai Life Sciences N.V., Vertical Aerospace Ltd., and Tilray Brands, Inc.
• Prime Medicine, Inc. in connection with its $144.2 million follow-on offering, $300 million at-the-market offering, and day-to-day governance and reporting matters
• Biomea Fusion, Inc. in connection with its $37.1 million follow-on offering, $100 million at-the-market offering, and day-to-day governance and reporting matters
• Ocugen, Inc. in connection with its $30 million secured credit facility and day-to-day governance and reporting matters
• Absci Corporation’s $50 million follow-on offering
• Pairwise Plant Services Inc. in its formation of a joint venture company in collaboration with Corteva Agriscience LLC
• Pairwise Plants, LLC in its Series C financing and Class F-1 financing
• Round Hill Technologies Inc. in its initial closing of its $2.6 million Series Preferred Stock financing
• ImmuNext, Inc. in its agreement with Royalty Pharma, in which Royalty Pharma acquired royalties and milestones on frexalimab for approximately $525 million in cash including estimated transaction costs
• Underwriters in PACS Group, Inc.’s $450 Million IPO